$AXNX News
Last published 3w ago
- 3w agoAXNXAxonex AI Group Limited Announces 2-for-5 Reverse Stock SplitGlobeNewswireHong Kong, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Axonex AI Group Limited (("Axonex" or the "Company", NASDAQ:AXNX), a Hong Kong-based company with a strategic focus on artificial intelligence (AI) and
- 3w agoMIMIAXNXAxonex AI Group Joins FLAIR’s Embodied AI International Applications Hub and Launches Education Humanoid TOMOGlobeNewswireCollaboration to Explore Real-world Applications in Education and Manufacturing Hong Kong, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Axonex AI Group Limited ("Axonex AI" or the "Company", together with
- 1mo agoMIMIAXNXAxonex AI Group Limited (NASDAQ: AXNX) Solidifies Transformation into an AI and Robotics-Focused CompanyGlobeNewswireFormerly Mint Incorporation Limited (NASDAQ:MIMI), the Company Unveils New Corporate Identity and Ticker to Reflect Strategic Focus on AI and Robotics as Its Primary Growth Engine Hong Kong, Oct. 09, 2026
- 1mo agoAXNXKMTSCAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of DirectorsBusiness WireCAIRDAC, SA, a pre-revenue stage medtech company developing a leadless, self-powered cardiac pacemaker (Autonomous Leadless Pacing System), today announced the appointment of Raymond W. Cohen as chairman of its board
- 1y agoAXNXKMTSNSPRRXSTRxSight, Inc. Appoints Raymond W. Cohen to Its Board of DirectorsGlobeNewswireALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,
- 1y agoMDTAXNXMedtronic, Inc. et al. vs Axonics Modulation Technologies, Inc. - AIA Trial, DismissedUS Patent Trial and Appeal Board
- 1y agoMDTAXNXMedtronic, Inc. et al. vs Axonics Modulation Technologies, Inc. - AIA Trial, DismissedUS Patent Trial and Appeal Board
- 1y agoMDTAXNXMedtronic, Inc. et al. vs Axonics Modulation Technologies, Inc. - AIA Trial, DismissedUS Patent Trial and Appeal Board
- 1y agoMDTAXNXMedtronic, Inc. et al. vs Axonics Modulation Technologies, Inc. - AIA Trial, DismissedUS Patent Trial and Appeal Board
- 1y agoBSXAXNXBoston Scientific Closes Acquisition of Axonics, Inc.PR NewswireBoston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company...
- 2y agoAXNXAxonics Reports Third Quarter 2024 Financial ResultsBusiness WireAxonics, Inc. (NASDAQ:AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial
- 2y agoAXNXAxonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in AustraliaBusiness WireAxonics, Inc. (NASDAQ:AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable sacral neuromodulation (SNM) system
- 2y agoAXNXAxonics Prevails in Patent Infringement Lawsuit with MedtronicBusiness WireAxonics, Inc. (NASDAQ:AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in U.S. District Court for the Central District of
- 2y agoAXNXAxonics Reports Second Quarter 2024 Financial ResultsBusiness WireGenerated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (NASDAQ:AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to
- 2y agoAXNXAxonics Receives Regulatory Approval for Recharge-Free SNM System in AustraliaBusiness WireAxonics, Inc. (NASDAQ:AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ recharge-free sacral neuromodulation (SNM)
- 2y agoAXNXAxonics Reports First Quarter 2024 Financial ResultsBusiness WireAxonics, Inc. (NASDAQ:AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the
- 2y agoBSXAXNXBoston Scientific Announces Results for First Quarter 2024PR NewswireBoston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported...
- 2y agoAXNXBSXAxonics Stockholders Approve Merger Agreement with Boston ScientificBusiness WireAxonics, Inc. (NASDAQ:AXNX) announced that its stockholders have voted today to adopt Axonics' merger agreement with Boston Scientific Corporation (NYSE:BSX). According to preliminary voting results from the special
- 2y agoAXNXAxonics Provides Update on Inter Partes Review ProceedingsBusiness WireAxonics, Inc. (NASDAQ:AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting. The
- 2y agoAXNXAxonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation SystemBusiness WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™
- 2y agoAXNXAxonics Responds to ITC Action by MedtronicBusiness WireAxonics, Inc. (NASDAQ:AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along with a parallel action in U.S. District Court for
- 2y agoAXNXAxonics Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsBusiness WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three
- 2y agoBSXAXNXBoston Scientific Announces Results for Fourth Quarter and Full Year 2023PR NewswireBoston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported ...
- 2y agoAMAMHARPAXNXCPEKuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoAXNXAXNX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Axonics to Boston ScientificGlobeNewswireMONSEY, N.Y., Jan. 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the $71.00 per share in cash pursuant to which Axonics, Inc. (NASDAQ:AXNX) ("Axonics") has agreed
- 2y agoBSXAXNXBoston Scientific Announces Agreement to Acquire Axonics, Inc.PR NewswireBoston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a...
- 2y agoAXNXBSXAxonics Reports Preliminary 4Q23 and Fiscal Year 2023 RevenueBusiness WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for
- 2y agoAXNXBSXAxonics Announces Definitive Agreement to be Acquired by Boston ScientificBusiness WireAxonics, Inc. (NASDAQ:AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE:BSX) for $71 in cash per share, representing an equity value of
- 2y agoAXNXAxonics to Present at the J.P. Morgan Healthcare ConferenceBusiness WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to present at the J.P. Morgan
- 2y agoAXNXBiVACOR Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of DirectorsBusiness WireBiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Raymond W. Cohen has been appointed chairman of its board of directors. Mr. Cohen is an
- 3y agoMDTAXNXMedtronic, Inc. et al. vs Axonics Modulation Technologies, Inc. - AIA Trial, AffirmedUS Patent Trial and Appeal Board
- 3y agoAXNXRevolutionizing Care: NeuroQure's Groundbreaking Path to Treating Genetic Intellectual DisabilitiesGlobeNewswireIRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroQure has embarked on a transformative journey aimed at revolutionizing the treatment landscape for Fragile X Syndrome and Autism Spectrum Disorder (ASD). With an
- 3y agoAXNXAxonics to Participate in November Investor ConferencesBusiness WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following
- 3y agoAXNXAxonics, Inc. (AXNX) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoAXNXAxonics Reports Third Quarter 2023 Financial ResultsBusiness WireGenerated quarterly revenue of $93.1 million, an increase of 32% year over year Fiscal year 2023 revenue guidance increased to $362 million Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is
- 3y agoAXNXAxonics to Report Third Quarter 2023 Financial Results on October 30Business WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report third quarter 2023
- 3y agoAXNXAxonics to Participate in September Investor ConferencesBusiness WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following
- 3y agoAXNXAxonics Announces CFO Retirement and Appoints SuccessorBusiness WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Dan L. Dearen, president
- 3y agoAXNXAxonics Reports Second Quarter 2023 Financial ResultsBusiness WireGenerated quarterly revenue of $92.9 million, an increase of 35% year over year Fiscal year 2023 revenue guidance increased to $358 million Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is
- 3y agoAXNXAxonics to Report Second Quarter 2023 Financial Results on July 27Business WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2023 financial
- 3y agoAXNXAxonics Reports First Quarter 2023 Financial ResultsBusiness WireGenerated quarterly revenue of $70.7 million, an increase of 46% year over year Fiscal year 2023 revenue guidance increased to $348 million Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is
- 3y agoAXNXAxonics to Participate in Upcoming Investor ConferencesBusiness WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following
- 3y agoAXNXAxonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral NeuromodulationBusiness WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the acquisition of a lead
- 3y agoAXNXAxonics to Report First Quarter 2023 Financial Results on May 1Business WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report first quarter 2023
- 3y agoAXNXAxonics Ranked No. 2 on the Financial Times 2023 List of the Fastest Growing Companies in the AmericasBusiness WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 2 on the Financial
- 3y agoAXNXAxonics, Inc. - Appeal, ReversedUS Patent Trial and Appeal Board
- 3y agoAXNXAxonics to Participate in the SUFU 2023 Winter MeetingBusiness WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is participating as a platinum sponsor of the
- 3y agoAXNXAxonics Reports Fourth Quarter and Fiscal Year 2022 Financial ResultsBusiness WireGenerated record quarterly revenue of $86 million, an increase of 62% y/y Reported fiscal year 2022 revenue of $274 million, an increase of 52% y/y Reiterated fiscal year 2023 revenue guidance of $342 million, an
- 3y agoAXNXAxonics to Report Fourth Quarter 2022 Financial Results on March 1Business WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter 2022 financial
- 3y agoAXNXAxonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation SystemBusiness WireAxonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug